Moderna, Inc. (MRNA) has seen some recent movement in the market and its stock finished trading at $47.93 yesterday. People are starting to take notice of MRNA as the stock traded as high as $50.50 and as low as $48.00 in the last trading day.

Moderna, Inc. (MRNA) average trading volume is 16.76M. However, in the last trading day Moderna, Inc. (MRNA) exchanged 10,402,144 shares. The 1st support level on MRNA is $46.75 and the 1st upside resistance level on MRNA is $59.41. MRNA 50day moving average is $36.70 and MRNA 200 day moving average is $24.21.

Moderna, Inc. (MRNA) most current performance has been specified by the recent movement in MRNA stock. MRNA has performed 52.11% over the past 4 weeks, MRNA has performed 147.79% over the past 3 months and MRNA has shown 85.66% over the past 365 days. Moderna, Inc. (MRNA) has a 52 week range of $11.54 to $56.38. Moderna, Inc. (MRNA) is trading 337.61% from its 52 week low and -10.43% from its 52 week high. Moderna, Inc. (MRNA) is indicating a 9.54% short float indicating the quantity short in the float.

MRNA has 315.69M shares outstanding and 250.23M shares in the float. Moderna, Inc. (MRNA) at this time has a market cap of $15.94B and income of $-514.00M. The EPS next quarter for MRNA is -0.35 and projected EPS net year is 14.90%. The market cap of Moderna, Inc. (MRNA) at $15.94B represents how many People own shares of MRNA and is calculated off the last price ($47.93) of MRNA and the quantity of shares outstanding (315.69M) with Moderna, Inc. (MRNA).

Moderna, Inc. (MRNA) has aggregate cash (mrq) of 1.1B, aggregate cash per share (mrq) of 2.99, aggregate debt of MRNA is at 135.95M and aggregate debt/equity (mrq) is 11.57. Moderna, Inc. (MRNA) operational cash flow (ttm) is -458.97M and MRNA leveraged free cash flow (ttm) is -332.12M.

MRNA is trading 19.62% above (bullish) its SMA20, 53.36% above (bullish) its SMA50 and 138.20% above (bullish) its SMA200.

Recent News:

In recent news, on May 1, 2020, it was announced, Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus. In this news it stated, Collaboration goal to enable manufacturing of up to 1 billion doses per year Technology transfer expected to begin in June 2020

About Moderna, Inc. (MRNA):

Cambridge, MA-based Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company has several early to mid-stage pipeline candidates targeting multiple indications including cancer and cardiovascular.